THEMISMED Stock Overview
Manufactures and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for THEMISMED from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Themis Medicare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹232.20 |
| 52 Week High | ₹317.00 |
| 52 Week Low | ₹180.55 |
| Beta | 0.53 |
| 1 Month Change | -15.69% |
| 3 Month Change | -16.05% |
| 1 Year Change | 7.50% |
| 3 Year Change | 114.74% |
| 5 Year Change | 436.75% |
| Change since IPO | 1,709.82% |
Recent News & Updates
Recent updates
Investor Optimism Abounds Themis Medicare Limited (NSE:THEMISMED) But Growth Is Lacking
Jan 21
What Themis Medicare Limited's (NSE:THEMISMED) 42% Share Price Gain Is Not Telling You
Dec 27Themis Medicare (NSE:THEMISMED) Takes On Some Risk With Its Use Of Debt
Dec 01Themis Medicare (NSE:THEMISMED) Has Affirmed Its Dividend Of ₹5.00
Aug 18Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00
Aug 04Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00
Jul 18We Think Themis Medicare (NSE:THEMISMED) Is Taking Some Risk With Its Debt
Jul 08Themis Medicare (NSE:THEMISMED) Is Due To Pay A Dividend Of ₹5.00
May 18Themis Medicare (NSE:THEMISMED) Seems To Use Debt Quite Sensibly
Dec 21Themis Medicare (NSE:THEMISMED) Has Announced That It Will Be Increasing Its Dividend To ₹5.00
Aug 28Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹5.00
Aug 08Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's
Jul 21Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's
May 27Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?
May 12Calculating The Fair Value Of Themis Medicare Limited (NSE:THEMISMED)
Nov 09Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?
Oct 26Increases to Themis Medicare Limited's (NSE:THEMISMED) CEO Compensation Might Cool off for now
Sep 11Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹4.30
Aug 16Do Themis Medicare's (NSE:THEMISMED) Earnings Warrant Your Attention?
Jul 09Shareholder Returns
| THEMISMED | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.3% | 3.4% | 1.6% |
| 1Y | 7.5% | 19.3% | 5.5% |
Return vs Industry: THEMISMED underperformed the Indian Pharmaceuticals industry which returned 19.3% over the past year.
Return vs Market: THEMISMED exceeded the Indian Market which returned 5.5% over the past year.
Price Volatility
| THEMISMED volatility | |
|---|---|
| THEMISMED Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: THEMISMED has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: THEMISMED's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,509 | Sachin Patel | www.themismedicare.com |
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) and formulations for use in various therapeutic areas, including anti-tuberculosis, anti-malarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition, anaesthesia, gynecology, and orthopedics. It also offers anti-inflammatory drugs and other drugs.
Themis Medicare Limited Fundamentals Summary
| THEMISMED fundamental statistics | |
|---|---|
| Market cap | ₹21.81b |
| Earnings (TTM) | ₹529.90m |
| Revenue (TTM) | ₹4.20b |
40.4x
P/E Ratio5.1x
P/S RatioIs THEMISMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THEMISMED income statement (TTM) | |
|---|---|
| Revenue | ₹4.20b |
| Cost of Revenue | ₹1.51b |
| Gross Profit | ₹2.70b |
| Other Expenses | ₹2.17b |
| Earnings | ₹529.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 5.76 |
| Gross Margin | 64.13% |
| Net Profit Margin | 12.61% |
| Debt/Equity Ratio | 19.8% |
How did THEMISMED perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield9%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 12:50 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Themis Medicare Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |